Leading the way to a cure

Lupus Research Update: 2007 Volume 1

Volume 1, 2007 - Online Edition | In This Issue

The results are in! >
ALR's 2007 grant recipients >
One Love. One Cause. ALR Gala a Smashing Success >
The Faces of Lupus >
Advocacy Update — ALR Goes to Washington >
Research Results - Rituximab Results in Long-Term Immune Alteration in Some Lupus Patients >
Research Results — Exploring Toll-Like Receptors’ (TLR) Role in Lupus >
Research Results – The Role of Myeloid Dendritic Cells in Lupus >
News Flash – American College of Rheumatology Annual Meeting Update >
FDA Warning on Rituximab >
Drug Research and Development News >
Beyond the Research - 2007 Walk Sites Announced >

FDA Warning on Rituximab

In December, the Food and Drug Administration warned health care professionals and patients that two people with lupus treated with rituximab (Rituxan) developed progressive multifocal leukoencephalopathy, a fatal viral infection of the central nervous system. The infection can also occur in nonlupus patients treated with the drug and in other people with compromised immune systems who were not treated with rituximab. Currently, rituximab is only approved for use in patients with non-Hodgkin lymphoma and for those with rheumatoid arthritis whose disease has not responded to other therapies.


1.5 million

people in the U.S. have Lupus.

172 million

dollars committed to lupus research by the Lupus Research Alliance.

We're walking across the United States to raise awareness and funds for lupus research.


Show your support by visiting the Lupus Research Alliance online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.

Powered by Blackbaud
nonprofit software